FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1664-1666 October 18, 2007 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Hudis, C. A. PubMed Citation

To the Editor: In his review of trastuzumab, Hudis (July 5 issue)¹ notes that major research efforts are focused on identifying new predictive markers for tailored decisions regarding cancer treatment. The ErbB receptor family has a key role in carcinogenesis. Among its members, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2) are now successfully targeted by biologic agents used in cancer therapeutics.^1,2 However, the limited efficacy of trastuzumab in some patients with breast cancer indicates that other factors besides HER2 status are important for the proliferation of breast-cancer cells.

The role of ligands has . . . [Full Text of this Article]

This article has been cited by other articles:

• Karamouzis, M. V., Konstantinopoulos, P. A., Papavassiliou, A. G. (2008). ErbB/HER receptor family in breast cancer--the more we search the more we learn. Ann Oncol 19: 1020-1021 [Full Text]